| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WALTHAM, Mass.—In late January, Thermo Electron announced that it would dramatically enhance its product portfolio by acquiring Kendro Laboratory Products, a division of SPX Corp. The acquisition will cost the multinational instrument market leader $833.5 million in cash, subject to a post-closing balance sheet adjustment. To finance a portion of the purchase price, Thermo received a commitment for a credit facility of $600 million.
 
Kendro designs and manufactures a variety of laboratory products for use in sample preparation, processing, and storage, including incubators and ovens, freezers and refrigerators, and centrifuges. It marketed these items to industrial, academic, and clinical facilities under brand names like Heraeus, Revco, and Sorvall. In 2004, Kendro was estimated to have sales of $365 million.
 
While Thermo also carries basic support instrumentation, such as water baths, centrifuges, and vacuum driers, the company has largely developed its reputation on the basis of its more complex analytical instrumentation, in-cluding a long line of hyphenated spectrometry equipment, as well as chromatography instruments and LIMS.
 
The acquisition is just the latest such move for Thermo, which in the last two years has purchased LIMS specialist InnaPhase and laboratory products provider Jouan. These moves, like this one, extended Thermo's market reach and may remind people of a similar extension and consolidation that Thermo Electron experienced a few years ago when it brought many subsidiaries under the Thermo Electron umbrella.
 
For SPX, the sale of Kendro is just one of several such divestitures—the latest being Edwards Systems Technology fire safety systems to General Electric and BOMAG compaction equipment to Fayat—as the company begins to take a "good strategic look" at every company in the SPX portfolio to see how it can make SPX stronger, improving profitability for shareholders and associates. While Kendro has generated substantial profits and cash flow for SPX, the company expects the sale will unlock additional value for SPX shareholders.
 
By early March, Thermo an-nounced that the Federal Trade Commission had granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. At press time, the closing of the transaction, however, remain-ed subject to other conditions and regulatory approvals which prevented officials from either Thermo or Kendro from commenting for this story.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue